ELZONRIS (tagraxofusp-erzs) injection, for intravenous use. Initial U.S. Approval: 2018

ELZONRIS (tagraxofusp-erzs) injection, for intravenous use. Initial U.S. Approval: 2018

INDICATIONS AND USAGE
ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
DOSAGE FORMS & STRENGTHS
Elzonris 1000 mcg/1 mL single dose vial: 10 vials per 21 day cycle.
Manufactured By: Stemline Therapeutics, Inc.
Prescribing Information URL: Click Here

Access to ELZONRIS (tagraxofusp-erzs) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.